(PC) Witkin v. Lotersztain

CourtDistrict Court, E.D. California
DecidedJune 23, 2022
Docket2:19-cv-00406
StatusUnknown

This text of (PC) Witkin v. Lotersztain ((PC) Witkin v. Lotersztain) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
(PC) Witkin v. Lotersztain, (E.D. Cal. 2022).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE EASTERN DISTRICT OF CALIFORNIA 10 11 MICHAEL WITKIN, No. 2:19-cv-0406 TLN KJN P 12 Plaintiff, 13 v. ORDER 14 MARIANA LOTERSZTAIN, M.D., et al., 15 Defendants. 16 17 Plaintiff is a state prisoner, proceeding without counsel. Two motions filed by plaintiff 18 are pending: a motion to exclude opinion testimony of expert Dr. Burgar under Daubert v. 19 Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) (“Daubert I”); and a motion for 20 discovery. Defendant Lin opposes both motions. As set forth below, plaintiff’s motions are 21 denied, and plaintiff is directed to file his oppositions to defendants’ pending motions for 22 summary judgment. 23 I. Motion to Exclude 24 A. The Parties’ Arguments 25 Plaintiff’s Motion 26 Plaintiff seeks to exclude the opinion testimony of defendant Lin’s expert witness, 27 Alexandra Burgar, “on the basis that the opinion testimony is not based on sufficient facts or data, 28 is not grounded in medical science, is unexplained and unhelpful, and is not sufficiently reliable 1 to withstand scrutiny under Rule 702.” (ECF No. 59 at 1.) He contends Dr. Burgar failed to set 2 forth the standard of care and is therefore not relevant, and failed to explain her methodology or 3 provide any peer consensus or medical literature to support her conclusion that splinting was the 4 appropriate treatment for a comminuted intra-articular fracture of the fourth proximal phalanx. 5 (ECF No. 59 at 3, 5-6.) Plaintiff objects that Dr. Burgar failed to explain the potential severity of 6 the fracture and how it impacted treatment options, the effect of the time lapse on the treatment 7 options, whether the initial treatment was beneficial or harmful, or how the nature and extent of 8 plaintiff’s injury impacted the course of treatment. (ECF No. 59 at 3.) 9 Plaintiff argues that Dr. Burgar’s opinion testimony is not good science and does not 10 advance Dr. Lin’s malpractice defense because her opinion is conclusory and fails to provide any 11 factual basis, simply providing “her bald ‘assurances of reliability. Under Daubert, that’s not 12 enough.’” (ECF No. 59 at 6) (quoting Daubert v. Merrell Dow Pharm., Inc., 43 F.3d 1311, 1319 13 (9th Cir. 1995) (“Daubert II”). Specifically, plaintiff seeks to strike (id. at 7) paragraphs 4, 7 and 14 8 of Dr. Burgar’s declaration: 15 4. It is my opinion that Dr. Lin complied with the standard of care with respect to the care and treatment he provided to Mr. Witkin. 16 Specifically, Dr. Lin’s examination and x-ray images revealed a comminuted and intra-articular fracture of the fourth proximal 17 phalanx, with mild degenerative changes. Given Dr. Lin exam findings, the x-ray report, and the history of the injury, Dr. Lin’s 18 determination at the time that surgery was not more likely to provide a better result than splinting was correct, and consistent with the 19 standard of care. Moreover, surgery on Mr. Witkin’s finger could have resulted in a worse outcome for Mr. Witkin, and therefore 20 splinting was the preferred course. 21 7. The care and treatment provided to Mr. Witkin by Dr. Lin complied in all respects with the standard of care. 22 8. Given the location of Mr. Witkin’s fracture, the type of fracture, 23 and his pre-existing arthritis (documented on his x-ray as degenerative changes), the finger deformation, loss of function, and 24 improper healing claimed by Mr. Witkin was, more likely than not, a result of the initial fracture, and not the medical care, or any lack 25 of medical care, on the part of Dr. Lin. 26 (ECF No. 55-2 at 120-21.) 27 Defendant’s Opposition 28 Defendant Lin opposes plaintiff’s motion, arguing that Dr. Burgar’s declaration 1 establishes that she is a physician with extensive experience and knowledge in treating conditions 2 affecting the bones, muscles, nerves and tendons of the hand, and her opinions are based on a 3 review of plaintiff’s pertinent medical records, plaintiff’s deposition, and Dr. Lin’s declaration. 4 (ECF No. 63 at 5-6.) Such review supported Dr. Burgar’s conclusion that Dr. Lin’s care was 5 consistent with the standard of care for treating plaintiff’s fracture. The standard of care is a 6 central issue in this case and is not a matter within the general knowledge of lay people. Thus, 7 Dr. Burgar’s declaration should be admitted because there is sufficient evidence to support its 8 reliability and her testimony will assist the trier of fact to understand the issue. 9 Defendant argues that Dr. Burgar was not required to address potential treatment or 10 findings that Dr. Lin could have made that also would have complied with the standard of care; 11 rather, the issue here is whether the treatment Dr. Lin actually provided complied with the 12 standard of care. If Dr. Burgar had concluded that Dr. Lin did not recommend the appropriate 13 treatment, then Dr. Burgar would have likely needed to state what treatment she would have 14 recommended. But because Dr. Burgar found that Dr. Lin’s decision complied with the standard 15 of care, she was not required to identify all decisions that would have complied with the standard 16 of care. Defendant contends that “[b]y stating that the treatment Dr. Lin provided was one which 17 is in compliance with the standard of care, she has articulated what treatment would comply 18 with the standard.” (ECF No. 63 at 6.) 19 Further, to the extent plaintiff argues that Dr. Burgar failed to consider relevant 20 information or might have been able to obtain more complete information, such facts go to the 21 weight to be given to her opinions, not the admissibility of her opinions. (ECF No. 63 at 6.) 22 (citing see Hangarter v. Provident Life and Acc. Ins. Co., 373 F.3d 998, 1017 n.14 (9th Cir. 2004) 23 (“[T]he factual basis of an expert opinion goes to the credibility of the testimony, not the 24 admissibility, and it is up to the opposing party to examine the factual basis for the opinion in 25 cross-examination.”) 26 Plaintiff’s Reply 27 In reply, plaintiff argues that Dr. Burgar’s opinion is a legal opinion created expressly for 28 purposes of testifying, not a medical opinion. Plaintiff contends that Dr. Burgar’s declaration 1 fails to explain why splinting was the appropriate course of medical treatment rather than a closed 2 or open reduction of plaintiff’s fracture, or explain the facts or clinical circumstances under which 3 splinting would be medically appropriate. (ECF No. 69.) Plaintiff reiterates that Dr. Burgar 4 failed to set forth the applicable standard of care or provide any explanation as to why her 5 experience is a sufficient basis for her conclusory opinion. 6 B. Governing Standards 7 Federal Rule of Evidence 702 allows a qualified expert to testify “in the form of an 8 opinion or otherwise” where: (a) the expert’s scientific, technical, or other specialized knowledge 9 will help the trier of fact to understand the evidence or to determine a fact in issue; (b) the 10 testimony is based on sufficient facts or data; (c) the testimony is the product of reliable 11 principles and methods; and (d) the expert has reliably applied the principles and methods to the 12 facts of the case. Fed. R. Evid. 702. In evaluating expert opinion testimony, federal courts apply 13 a more flexible Daubert standard. Daubert I, 509 U.S. at 579.1 Expert testimony is admissible 14 under Rule 702 if the expert is qualified and if the testimony is both relevant and reliable. See 15 Daubert I, 509 U.S. at 597; see also Messick v. Novartis Pharms.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Primiano v. Cook
598 F.3d 558 (Ninth Circuit, 2010)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Engelhardt v. S.P. Richards Co.
472 F.3d 1 (First Circuit, 2006)
United States v. Lavern Hankey, AKA Poo, Opinion
203 F.3d 1160 (Ninth Circuit, 2000)
United States v. Richard Joseph Finley
301 F.3d 1000 (Ninth Circuit, 2002)
Lisa Stilwell v. Smith & Nephew, Inc., a Corporation
482 F.3d 1187 (Ninth Circuit, 2007)
People v. Kelly
549 P.2d 1240 (California Supreme Court, 1976)
Blough v. Holland Realty, Inc.
574 F.3d 1084 (Ninth Circuit, 2009)
O'NEILL v. Novartis Consumer Health, Inc.
55 Cal. Rptr. 3d 551 (California Court of Appeal, 2007)
Johnson v. Superior Court
49 Cal. Rptr. 3d 52 (California Court of Appeal, 2006)
Jennings v. Palomar Pomerado Health Systems, Inc.
8 Cal. Rptr. 3d 363 (California Court of Appeal, 2003)
Hanson v. Grode
90 Cal. Rptr. 2d 396 (California Court of Appeal, 1999)
McClellan v. I-Flow Corp.
710 F. Supp. 2d 1092 (D. Oregon, 2010)
Linda Messick v. Novartis Pharmaceuticals Corp.
747 F.3d 1193 (Ninth Circuit, 2014)
United States v. Santiago-Burgos
750 F.3d 19 (First Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
(PC) Witkin v. Lotersztain, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pc-witkin-v-lotersztain-caed-2022.